Premium
Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for central serous chorioretinopathy: a case series
Author(s) -
MAIER M,
VALET V,
FEUCHT N,
FIORE B,
WINKLER VON MOHRENFELS C,
LOHMANN CP
Publication year - 2008
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2008.650.x
Subject(s) - verteporfin , medicine , bevacizumab , serous fluid , photodynamic therapy , ophthalmology , visual acuity , fluorescein angiography , combination therapy , retinal , surgery , choroidal neovascularization , chemotherapy , chemistry , organic chemistry
Purpose To discuss the effect and outcome of a combined photodynamic therapy and intravitreal injection of Bevacizumab in treating central serous chorioretinopathy (CSC). Methods 4 Patients with chronic central serous chorioretinopathy (CSC) were treated with intravitreal injection of 1,25 mg Bevacizumab administered within 24 hours after standard PDT laser treatment (83 sec., 689nm) with Verteporfin. (5,7ml Verteporfin over 10 min. intravenousely). Before, 3, and 6 month after treatment visual acuity, OCT examinations (retinal thickness) and fluorescein angiography were performed. Results Mean visual acuity increased from baseline 20/50, to 20/25 after 3 month. Subretinal fluid almost resolved completely after treatment. OCT‐ and FLA‐ findings are presented in our patients. OCT 1, 3 and 6 month after combination therapy showed a reduced retinal thickness compared to baseline. 1 patient had full recovered vision after 6 month. Conclusion Photodynamic therapy combined with injection of intravitreal Bevacizumab was very effective in our patients. Current literature depicts medical treatment, focal laser, SRT and PDT as treatment options for CSC. To our knowledge this is the first report of a combination therapy in CSC. The treatment was well tolerated and we did not see any complications. The patients presented with ongoing recovered vision during follow up. Further experience is necessary to evaluate the treatment option of PDT and Avastin® combination therapy especially in chronic central serous chorioretinopathy (CSC).